LOCALLY RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Clinical trials for LOCALLY RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCALLY RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for LOCALLY RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to boost survival in head and neck cancer
Disease control Recruiting nowThis phase II trial tests whether adding chemotherapy or chemo-immunotherapy before standard salvage surgery helps patients with recurrent or persistent head and neck cancer. About 180 participants with PD-L1 positive tumors will receive either carboplatin and paclitaxel, or thos…
Matched conditions: LOCALLY RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 23, 2026 16:46 UTC
-
Drug combo aims to shrink returning oral tumors before surgery
Disease control Recruiting nowThis phase 2 trial tests whether giving two drugs, cemiplimab and cetuximab, before salvage surgery can help control recurrent oral cavity squamous cell carcinoma. The study will enroll 17 adults whose cancer has returned at least 3 months after prior treatment. Researchers will …
Matched conditions: LOCALLY RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 11:54 UTC
-
Biomarker-Guided combo aims to outsmart resistant cancers
Disease control Recruiting nowThis phase II trial is testing whether the combination of cabozantinib (a targeted drug) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head/neck cancers that have stopped responding to prior immunotherapy. Researchers will also see if two tumor bi…
Matched conditions: LOCALLY RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC